The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Results of a Phase II trial investigating loncastuximab tesirine + rituximab in high-risk R/R FL
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, presents the results of a Phase II investigator-initiated study (NCT04998669) investigating a combination of loncastuximab tesirine and rituximab in patients with high-risk relapsed/refractory (R/R) follicular lymphoma (FL). Dr Alderuccio highlights that robust and durable complete metabolic responses (CMR) were observed in a high proportion of patients. The progression-free survival (PFS) and overall survival (OS) at 12 months were highly encouraging, and the study demonstrates the potential of this treatment approach in improving outcomes for patients with high-risk disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This was an investigator-initiated study that included 39 patients enrolled at the University of Miami. Those patients presented high-risk features such as progression of disease within 24 months after immunotherapy and/or a high disease burden by GELF criteria. Those patients received loncastuximab tesirine at the approved dose of 1.5 milligrams per kilogram in the first two cycles and subsequently decreased to 1...
This was an investigator-initiated study that included 39 patients enrolled at the University of Miami. Those patients presented high-risk features such as progression of disease within 24 months after immunotherapy and/or a high disease burden by GELF criteria. Those patients received loncastuximab tesirine at the approved dose of 1.5 milligrams per kilogram in the first two cycles and subsequently decreased to 1.0 milligrams per kilogram and also rituximab for weekly doses. And the primary study endpoint was the CR rate of week 12 and we observed that almost 70 percent of the patients achieved complete responses and those responses this year increased to almost 80 percent, 77%, at week 21 for a best overall response rate of 97%. And the progression-free survival and overall survival in those patients is about 90% at 12 months and we’ve not reached median progression-free survival and/or overall survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Regeneron: Consultancy; AbbVie: Consultancy; Genmab: Research Funding; BeiGene: Research Funding; ADC Therapeutics: Consultancy, Research Funding; Genentech: Consultancy.
